A Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeated Subcutaneous (SC) Doses of REMD-477 in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase I/II
Latest Information Update: 09 Feb 2017
At a glance
- Drugs REMD 477 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors REMD Biotherapeutics
- 16 Aug 2016 An additional treatment arm has been added for REMD-477 in Combination with Metformin, Planned number of patients changed from 72 to 102.
- 16 Aug 2016 Planned End Date changed from 1 Jul 2017 to 1 Nov 2017.
- 16 Aug 2016 Planned primary completion date changed from 1 May 2017 to 1 Sep 2017.